IGF2 and neoplasm: First, we used eight known enhancer hijacking target genes including MYC (9), BCL2 (8), CCNE1 (37), TERT (7), IGF2 (13,37) (in two tumor types), IGF2BP3 (38) and IRS4 (13) to test the sensitivities.